• LAST PRICE
    18.2000
  • TODAY'S CHANGE (%)
    Trending Up0.0800 (0.4415%)
  • Bid / Lots
    18.0800/ 3
  • Ask / Lots
    18.4700/ 1
  • Open / Previous Close
    18.0800 / 18.1200
  • Day Range
    Low 17.9100
    High 18.2000
  • 52 Week Range
    Low 4.1850
    High 19.5000
  • Volume
    60,817
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 18.12
TimeVolumeMOR
09:32 ET41518.14
09:34 ET865718.04
09:36 ET12318.03
09:38 ET124918.01
09:43 ET20018.1
09:48 ET203418.105
09:52 ET20018.1059
10:10 ET581718.12
10:24 ET10018.12
10:28 ET10018.13
10:30 ET80818.11
10:35 ET10018.105
10:48 ET13618.11
11:11 ET1048418.18
11:15 ET10018.17
11:38 ET81318.14
11:42 ET250018.13
11:44 ET22718.14
12:23 ET75018.185
12:59 ET10018.175
01:06 ET110018.18
01:33 ET10018.2
01:35 ET10018.2
01:44 ET41818.2
01:50 ET32018.2
02:29 ET45118.2
03:18 ET10018.15
03:32 ET40018.19
03:34 ET48218.2
03:38 ET60018.2
03:39 ET39418.2
03:41 ET46418.2
03:45 ET25518.18
03:48 ET10018.19
03:50 ET56518.2
03:52 ET16918.2
03:54 ET10018.19
03:56 ET150018.2
03:57 ET20018.2
03:59 ET99718.2
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMOR
MorphoSys AG
2.7B
-5.4x
---
United StatesTWST
Twist Bioscience Corp
2.9B
-14.6x
---
United StatesARWR
Arrowhead Pharmaceuticals Inc
2.9B
-5.6x
---
United StatesDNLI
Denali Therapeutics Inc
2.9B
-22.2x
---
United StatesADMA
ADMA Biologics Inc
2.5B
-525.0x
---
United StatesTGTX
TG Therapeutics Inc
2.6B
77.0x
---
As of 2024-06-21

Company Information

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Contact Information

Headquarters
Semmelweisstr. 7PLANEGG, Germany 82152
Phone
---
Fax
898-992-7222

Executives

Independent Chairman of the Supervisory Board
Marc Cluzel
Chairman of the Management Board, Chief Executive Officer
Jean-Paul Kress
Independent Deputy Chairman Member of the Supervisory Board
George Golumbeski
Chief Financial Officer, Member of the Executive Committee
Lucinda Crabtree
Senior Vice President, Head of Corporate Affairs, Member of the Executive Committee
Thomas Biegi

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.7B
Revenue (TTM)
$218.6M
Shares Outstanding
150.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.20
EPS
$-3.37
Book Value
$0.35
P/E Ratio
-5.4x
Price/Sales (TTM)
12.5
Price/Cash Flow (TTM)
---
Operating Margin
-220.81%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.